logo-loader
Health

Kazia Therapeutics reaches milestone for Phase 1 Cantrixil trial in ovarian cancer

Kazia Therapeutics Limited (ASX:KZA) chief executive officer Dr James Garner updates Proactive Investors on a milestone for the company, with the completion of recruitment for Cantrixil its Phase 1 clinical trial in ovarian cancer.

The CEO said the first part of the study has shown some very promising signals, and the data from Part B will significantly enhance understanding of the drug.

The company will be presenting data to the upcoming ESMO conference in September.

Kazia is also making news with its treatment strategies for different types of brain cancer.

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: hVIVO PLC's 2020 pipeline 'looking strong' as it expands...

hVIVO PLC's (LON:HVO) executive chairman Trevor Phillips tells Proactive London's Andrew Scott the business is now better positioned to be profitable next year. The creator of pioneering human disease models based upon viral challenge generated revenues of £5.9mln in the six months ended June...

7 hours, 22 minutes ago

2 min read